Clinical Trials

  • Program for Overweight Education and Reduction (POWER)

    We are doing this research study to find out about what happens to children who are overweight and how the things we recommend as a part of routine clinical care affect your child. The purpose of this study is to understand what happens to children as a result of being overweight, to link these outcomes to specific clinical measures and to determine how treatment affects the physical and clinical features of overweight or obesity. To achieve this aim we want to formalize our ongoing clinical chart review into a database for our patients.

  • PVDOMICS: Defining the Future Fingerprints of Pulmonary Vascular Disease

    This research study is being conducted to study pulmonary hypertension and right heart dysfunction based on clinical, imaging, physiological and pathological characteristics. We hope to develop a new classification system and new methods to diagnose and treat pulmonary hypertension. Diagnostic testing includes (listed subsequently): full medical work-up, minimal blood collection, right heart catheterization, echocardiogram, ekg, take home sleep oximetry study, six-minute walk, exercise test, Pulmonary function test, Lung CT, Questionnaires, ventilation/perfusion scan and cardiac MRI.

  • Registry for Asthma Characterization and Recruitment 2 for children 6-17 years with asthma - English and Spanish

    Asthma registry to maintain and expand a database of participants with asthma who may be able to participate in future Inner City Asthma Consortium studies.

  • Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients (6 months-17 years)

    The purpose of this study is to find out the effects and safety of an investigational (experimental) new drug called copanlisib in pediatric patients from 6 months to 21 years of age. This study consists in two phase, Phase I part will determine which is the right dose of copanlisib to be used in children/adolescents/adults with relapsed (has returned) or refractory (did not respond to standard treatment) solid tumor or lymphoma.

  • Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients (ages 18-21)

    The purpose of this study is to find out the effects and safety of an investigational (experimental) new drug called copanlisib in pediatric patients from 6 months to 21 years of age. This study consists in two phase, Phase I part will determine which is the right dose of copanlisib to be used in children/adolescents/adults with relapsed (has returned) or refractory (did not respond to standard treatment) solid tumor or lymphoma.

  • Study Evaluating KTE-C19 in Adolescent Subjects With Acute Lymphoblastic Leukemia or B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

    Principal Investigator

    Prakash Satwani, MD
    The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.

  • Study Evaluating KTE-C19 in Pediatric Subjects With Acute Lymphoblastic Leukemia or B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

    Principal Investigator

    Prakash Satwani, MD
    The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.

  • Study of Combination of Drugs in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

    This is a Phase 1/2 multicenter study of lenvatinib administered in combination with everolimus inpediatric patients with relapsed or refractory solid tumors, including CNS tumors. The study treatment is considered experimental because lenvatinib is not approved by the United States(US) Food and Drug Administration (FDA) for treating pediatric patients with refractory solid tumors, including CNS tumors. The purpose of this study is to determine the highest safe dose of lenvatinib administered in combination with everolimus.

  • Study of Entrectinib in Children and Adolescents with Solid Tumors and Primary CNS Tumors

    The purpose of this study is to find out more about how the study drug called entrectinib will be used in children, adolescents and young adults with treatment-resistant solid tumor in brain or body. This is a phase 1/1b study, divided into a dose escalation portion (different dose will be tested) and a dose expansion portion (one dose will be tested) in participants with relapsed (has returned) or refractory (did not respond to standard treatment) neuroblastoma or participants whose cancer was previously shown via molecular testing to have specific changes in cancer cells.

  • Study of Experimental Drug in Pediatric Patients with Solid Tumors, including CNS Tumors

    This is a Phase 1 multicenter study of a drug called ABI-009 (nab-Rapamycin) in combination withtemozolomide and irinotecan in children and young adults with solid tumors (including CNS tumors)which have come back or have not responded to standard therapy. The study is considered experimental because ABI-009 (nab-Rapamycin) is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with tumors, including CNS tumors. Both temozolomide and irinotecan are drugs that are FDA-approved for other indications.

Pages